- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Soleno Therapeutics Inc (SLNO)
Soleno Therapeutics Inc stock price live, this page displays NASDAQ SLNO stock exchange data. View the SLNO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Soleno Therapeutics Inc real time stock price chart below.
What Is the Soleno Therapeutics Inc Stock Price Today?
The Soleno Therapeutics Inc stock price today is 53.0100.
What Is the Stock Symbol for Soleno Therapeutics Inc?
The stock symbol for Soleno Therapeutics Inc is "SLNO."
What Stock Exchange Does Soleno Therapeutics Inc Trade On?
Soleno Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Soleno Therapeutics Inc a Good Stock to Buy?
Determining whether Soleno Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SLNO quote. (ISIN: US8342033094)
What Is the Soleno Therapeutics Inc Stock Price Today?
The Soleno Therapeutics Inc stock price today is 53.0100.
What Is the Stock Symbol for Soleno Therapeutics Inc?
The stock symbol for Soleno Therapeutics Inc is "SLNO."
What Stock Exchange Does Soleno Therapeutics Inc Trade On?
Soleno Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Soleno Therapeutics Inc a Good Stock to Buy?
Determining whether Soleno Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SLNO quote. (ISIN: US8342033094)
53.0100
+0.0200(+0.04%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
52.9800
53.0100
52 wk Range
29.4300
90.3199
Showing Soleno Therapeutics historical data. For real-time data please try another search
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
52.980053.0100
52 wk Range
29.430090.3199
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SLNO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Currently not supported.
Analysts Sentiment
Neutral
Price Target
53.0000
Downside
-0.02%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Currently not supported.
- Form 13G Soleno Therapeutics For: 15 May
- Investing.com
- Form 8K Soleno Therapeutics Inc For: 18 May
- Investing.com
- Form 8K Soleno Therapeutics Inc For: 18 May
- Investing.com
Analyst Ratings
0 Buy
10 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 53.0000
(-0.02% Downside)
Soleno Therapeutics Inc SWOT Analysis
VYKAT XR Breakthrough | Explore Soleno's FDA-approved treatment for Prader-Willi Syndrome, addressing hyperphagia in a 12,000-patient U.S. market with potential global expansion |
Market Dynamics | Delve into VYKAT XR's commercial launch, pricing strategy, and early adoption metrics, with analysts projecting peak sales of up to $2.8 billion worldwide |
Financial Outlook | Discover Soleno's strong cash position of $290 million and analyst expectations of profitability, with EPS forecasts of $6.65 for FY2025 |
Analyst Consensus | Learn about the "Strong Buy" recommendation and median price target suggesting 37% upside, with targets ranging from $20 to $145 per share |
Soleno Therapeutics Inc Earnings Call Summary for Q4/2025
- Q4 EPS of $0.80 beat estimates by 31%, revenue hit $91.7M vs. $82.45M expected; stock rose 4.72% aftermarket to $39.28
- Net income reached $43.4M vs. $56M loss in Q4 2024, driven by successful VYKAT XR launch for Prader-Willi syndrome treatment
- Strong balance sheet with $506.1M cash and current ratio of 16.08; liquid assets substantially exceed short-term obligations
- Company projects continued EPS and revenue growth through 2026; analysts forecast profitability with expanding net income this year
- Management focuses on expanding U.S. market share and pursuing EU regulatory approval; risks include supply chain issues and market saturation
Last Updated: 2026-02-25, 05:38 p/m
Read Full TranscriptEarnings
Latest Release
May 07, 2026
EPS / Forecast
0.59 / 0.68
Revenue / Forecast
94.6M / 93.78M
Compare SLNO to Peers and Sector
Metrics to compare | SLNO | Peers Peers - average of corresponding metrics from companies closely matching SLNO: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipSLNOPeersSector |
|---|---|---|---|---|
P/E Ratio | 28.9x | 0.0x | −0.4x | |
PEG Ratio | 0.21 | 0.00 | 0.00 | |
Price/Book | 5.6x | 0.0x | 2.6x | |
Price / LTM Sales | 9.7x | 0.0x | 3.1x | |
Upside (Analyst Target) | 0.0% | 0.0% | 48.3% | |
Fair Value Upside | Unlock | 0.0% | 6.1% | Unlock |
People Also Watch
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.